Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Published Erratum
. 2023 Jun 27;22(1):101.
doi: 10.1186/s12943-023-01812-z.

Correction: Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials

Xianjing Chu #  1 , Wentao Tian #  1 , Ziqi Wang  1 , Jing Zhang  2 , Rongrong Zhou  3   4   5
Affiliations
Published Erratum

Correction: Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials

Xianjing Chu et al. Mol Cancer. .
No abstract available

PubMed Disclaimer

Figures

Fig. 2
Fig. 2
Mechanism of co-inhibition by TIGIT and PD-1. The TIGIT/CD226 pathway and the PD-1/PD-L1 pathway have an intersecting crossroad. On the one hand, upon activation by PD-L1, the intracellular domain of PD-1 recruits Shp2 to dephosphorylate CD226, inhibiting the immune activation function of CD226. On the other hand, TIGIT has a higher affinity (dissociation constant 1–3 nM) to CD155 than that of CD226 (dissociation constant 119 nM) [25], thus competitively antagonizes and blocks CD226 homodimerization through its extracellular domain, inhibiting the immune activation function of CD226
See this image and copyright information in PMC

Erratum for

References

    1. Chu X, Tian W, Wang Z, et al. Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials. Mol Cancer. 2023;22:93. doi: 10.1186/s12943-023-01800-3. - DOI - PMC - PubMed

Publication types